Key points
- FY26 revenue of $10.8 billion, up 15.5%
- Normalised EBIT of $1.09 billion, up 20.6%
- Net debt reduced to $663 million, Debt to Normalised EBITDA ratio at 0.57x
Full summary
Sigma Healthcare Limited (Sigma) announced its full-year results for FY26, marking its first full financial year post-merger with Chemist Warehouse Group (CWG). The company reported a revenue of $10.8 billion, up 15.5%, and normalized EBIT of $1.09 billion, up 20.6%. The Australian segment saw revenue growth of 14.9% and normalized EBIT growth of 18.3%, while the international segment experienced a 33.0% revenue increase and 91.3% EBIT growth. Sigma also delivered $32.6 million in integration synergies and reduced net debt to $663 million, maintaining a conservatively leveraged balance sheet.
Guidance
FY27 revenue and normalized EBIT guidance not provided in the announcement
Outlook
Sigma plans to grow its network, drive operating leverage, enhance product differentiation, and convert its platform into sustainable profit and cash generation for FY27.